MK-677 Side Effects: Clinical Data & What to Expect (2026)

Overview

MK-677, also known as ibutamoren or ibutamoren mesylate, is an orally active growth hormone secretagogue that mimics the action of ghrelin at the growth hormone secretagogue receptor (GHS-R1a). Unlike injectable GH-releasing peptides, MK-677 is taken orally and produces sustained elevations in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) over a 24-hour period. It has been studied in multiple clinical trials involving healthy elderly adults, obese subjects, and GH-deficient populations at doses of 10 mg to 50 mg daily, with most studies using 25 mg as the standard dose. While MK-677 has never received FDA approval, these clinical trials provide valuable dose-response safety data that inform our understanding of its side effect profile. Because MK-677 activates the ghrelin receptor — the same receptor stimulated by the hunger hormone ghrelin — many of its side effects are mechanistically predictable and directly related to ghrelin pathway activation and downstream GH/IGF-1 elevation. This guide examines each documented side effect using data from published clinical trials and peer-reviewed literature. This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before using any growth hormone secretagogue.

Appetite Increase: The Most Common Effect

Increased appetite is the single most frequently reported side effect of MK-677, affecting the vast majority of users at standard doses. This effect is a direct pharmacological consequence of MK-677 activating the ghrelin receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin — the body's primary hunger-signaling hormone. In the landmark study by Nass et al. (2008) examining MK-677 in healthy older adults over two years, appetite increase was reported by a substantial proportion of subjects in the treatment group. Chapman et al. (1996) demonstrated that 25 mg MK-677 daily significantly increased caloric intake in elderly subjects, with approximately 25-30% more calories consumed compared to placebo. The appetite stimulation is typically most pronounced during the first 4 to 8 weeks of use and may attenuate modestly with continued administration as partial desensitization of the ghrelin receptor occurs, though complete tolerance rarely develops. The hunger increase is not merely subjective — it translates to measurable increases in food intake and, if unchecked, body weight gain. In the two-year Nass study, MK-677-treated subjects gained an average of 2-3 kg more than the placebo group, primarily from increased caloric consumption. For users who are taking MK-677 for its GH-elevating properties but wish to avoid excessive weight gain, strategies include taking MK-677 at bedtime to sleep through the peak appetite window (onset approximately 30-60 minutes post-dose), starting at 10-15 mg rather than the full 25 mg dose, and pre-planning meals to prevent impulsive overeating during the appetite surge. The appetite stimulation can be beneficial for individuals who are underweight, recovering from illness, or struggling with age-related appetite decline — in these populations, it is a therapeutic effect rather than a side effect.

• Affects the majority of users at 25 mg daily — directly caused by ghrelin receptor activation
• Caloric intake increased approximately 25-30% in elderly subjects (Chapman et al., 1996)
• Most intense during the first 4-8 weeks, with partial attenuation over time
• Can lead to 2-3 kg weight gain over extended use if caloric intake is not controlled
• Mitigation strategies: bedtime dosing, lower starting dose (10-15 mg), meal pre-planning
• Beneficial in underweight, cachectic, or appetite-compromised populations

Water Retention and Bloating

Water retention is the second most commonly reported side effect of MK-677 and is a well-established consequence of growth hormone elevation. When MK-677 stimulates GH release, the downstream increase in IGF-1 activates the renin-angiotensin-aldosterone system (RAAS), promoting sodium and water reabsorption in the kidneys. This results in mild to moderate fluid accumulation that manifests as facial puffiness (particularly around the eyes upon waking), swollen ankles and feet, a bloated or distended abdominal appearance, increased body weight that does not reflect fat gain, and tighter-fitting rings or shoes. In clinical trials, peripheral edema was reported in approximately 5-10% of subjects at the 25 mg dose, though subclinical fluid retention likely affects a larger proportion of users. The water retention is typically most noticeable during the first 2 to 4 weeks of use as the body adjusts to sustained GH and IGF-1 elevation. Some degree of adaptation occurs over 4 to 8 weeks, but users often report persistent mild bloating throughout the duration of MK-677 use. The fluid retention is dose-dependent — lower doses (10-15 mg) produce less pronounced edema than the standard 25 mg dose. Managing MK-677-related water retention involves moderate sodium restriction (reducing but not eliminating dietary sodium), adequate potassium intake through foods like bananas, avocados, and leafy greens, staying well-hydrated (paradoxically, adequate water intake helps the body release excess fluid), and monitoring blood pressure, as fluid retention can modestly elevate readings in susceptible individuals. Individuals with pre-existing heart failure, kidney disease, or uncontrolled hypertension should avoid MK-677 due to the risk of clinically significant fluid overload. The water retention resolves within 1 to 2 weeks of discontinuing MK-677 as GH and IGF-1 levels return to baseline.

• Caused by GH-mediated activation of the renin-angiotensin-aldosterone system promoting sodium/water retention
• Peripheral edema reported in approximately 5-10% of clinical trial subjects at 25 mg
• Manifests as facial puffiness, ankle swelling, abdominal bloating, and tighter-fitting jewelry
• Most pronounced during weeks 1-4, with partial adaptation over 4-8 weeks
• Dose-dependent: lower doses (10-15 mg) produce less fluid retention
• Management: moderate sodium restriction, adequate potassium, proper hydration, blood pressure monitoring
• Resolves within 1-2 weeks of discontinuation

Blood Sugar Elevation and Insulin Resistance

MK-677 has a well-documented effect on glucose metabolism that represents one of its most clinically significant safety concerns, particularly with long-term use. Growth hormone is a counter-regulatory hormone that opposes insulin action, reducing glucose uptake in peripheral tissues and promoting hepatic glucose output. The sustained GH elevation produced by daily MK-677 administration can lead to measurable increases in fasting blood glucose and reductions in insulin sensitivity. In the two-year study by Nass et al. (2008) in healthy elderly adults, MK-677 at 25 mg daily increased fasting blood glucose by approximately 5-10 mg/dL compared to placebo. Fasting insulin levels also rose, reflecting compensatory pancreatic output to overcome GH-induced insulin resistance. HbA1c showed small but statistically significant increases in the treatment group. Notably, subjects with pre-existing impaired glucose tolerance or metabolic syndrome were at greater risk of clinically meaningful glucose elevations. In a study of obese subjects by Svensson et al. (1998), two months of MK-677 treatment produced a significant increase in fasting glucose and insulin concentrations, along with decreased insulin sensitivity measured by the homeostatic model assessment (HOMA-IR). Most concerning, some subjects in longer-duration studies developed new-onset impaired fasting glucose that met pre-diabetic thresholds. The glucose effects appear to be partially dose-dependent and are more pronounced in individuals with existing metabolic risk factors including obesity, family history of type 2 diabetes, sedentary lifestyle, and high-carbohydrate diets. Monitoring recommendations include baseline fasting glucose and HbA1c before starting MK-677, repeat testing at 4 to 8 weeks and every 3 months during continued use, and discontinuation if fasting glucose consistently exceeds 110-125 mg/dL or HbA1c rises above 5.7%. Individuals with type 2 diabetes or pre-diabetes should generally avoid MK-677 or use it only under close medical supervision with frequent glucose monitoring.

• Fasting blood glucose increases approximately 5-10 mg/dL on average at 25 mg daily (Nass et al., 2008)
• Fasting insulin rises as a compensatory response to GH-induced insulin resistance
• HbA1c shows small but statistically significant increases with long-term use
• Greater risk in individuals with pre-existing obesity, metabolic syndrome, or family history of diabetes
• Some subjects developed new-onset impaired fasting glucose in longer-duration studies
• Monitor fasting glucose and HbA1c at baseline, 4-8 weeks, and every 3 months during use
• Discontinue if fasting glucose consistently exceeds 110-125 mg/dL or HbA1c rises above 5.7%

Lethargy, Fatigue, and Sleep Effects

Lethargy and fatigue are commonly reported during the initial phase of MK-677 use, typically during the first 1 to 3 weeks. This effect has multiple contributing mechanisms. First, ghrelin receptor activation has sedative properties — endogenous ghrelin promotes sleep onset and increases slow-wave sleep duration, and MK-677 as a ghrelin mimetic produces similar effects. Second, the acute elevation in growth hormone promotes deep sleep by increasing slow-wave (stage 3 NREM) sleep, which is the most physically restorative sleep phase. Copinschi et al. (1997) demonstrated that MK-677 significantly increased the duration of stage 3 and stage 4 sleep in young healthy subjects, with a 50% increase in REM sleep duration and a 20% increase in overall sleep quality scores. While enhanced sleep quality is often cited as a benefit of MK-677, the initial sedating effect can feel like excessive drowsiness or lethargy during waking hours, particularly if MK-677 is taken in the morning or afternoon. This is why most experienced users recommend evening or bedtime dosing — it harnesses the sedative and sleep-promoting effects when they are desirable and minimizes daytime fatigue. The lethargy typically attenuates after 1 to 3 weeks of consistent use as the body adapts to the altered GH pulsatility pattern. However, some users report persistent mild lethargy with chronic use, particularly at higher doses. Lucid or vivid dreaming is another sleep-related effect frequently reported by MK-677 users. This is likely related to the increase in REM sleep duration documented by Copinschi et al. While not a safety concern, vivid dreams can be unsettling for some individuals. Dosing MK-677 at bedtime, starting at a lower dose, and allowing 2-3 weeks for adaptation typically resolves the most bothersome aspects of MK-677-related fatigue.

• Most pronounced during weeks 1-3, typically attenuates with continued use
• Caused by ghrelin receptor-mediated sedation and GH-induced deep sleep promotion
• MK-677 increased slow-wave sleep by 50% and REM duration by 20% in young subjects (Copinschi et al., 1997)
• Bedtime dosing strongly recommended to leverage sedative effects and minimize daytime fatigue
• Vivid or lucid dreaming commonly reported, related to increased REM sleep
• Lower starting doses (10-15 mg) reduce initial lethargy while allowing gradual adaptation

Joint Pain, Carpal Tunnel, and Musculoskeletal Effects

Musculoskeletal side effects including joint pain, joint stiffness, and carpal tunnel-like symptoms are recognized consequences of sustained GH and IGF-1 elevation from MK-677 use. These effects parallel those seen with exogenous growth hormone therapy and are caused by several interrelated mechanisms. Elevated IGF-1 stimulates connective tissue growth and collagen synthesis, which can cause soft tissue swelling in confined spaces such as the carpal tunnel, leading to median nerve compression and tingling, numbness, or pain in the hands and wrists. Fluid retention in joint spaces contributes to stiffness and reduced range of motion, particularly in the fingers, wrists, and ankles upon waking. In clinical trials at 25 mg daily, musculoskeletal complaints including arthralgia and myalgia were reported in approximately 5-15% of subjects, depending on the study population and duration. Elderly subjects appeared more susceptible to joint-related complaints than younger adults, likely because of pre-existing degenerative joint changes that are exacerbated by fluid retention and tissue remodeling. Carpal tunnel-like symptoms (paresthesia, numbness, and tingling in the hands) were reported at rates of approximately 3-8% in clinical trials and are among the more specific indicators of excessive GH/IGF-1 stimulation. These symptoms are typically dose-dependent and resolve with dose reduction or discontinuation. If carpal tunnel symptoms persist or worsen despite dose adjustment, nerve conduction studies may be warranted to rule out structural compression requiring intervention. For managing joint-related side effects, strategies include reducing the MK-677 dose from 25 mg to 10-15 mg, taking periodic breaks (5 days on, 2 days off or cycling 8 weeks on, 4 weeks off), using wrist splints at night if carpal tunnel symptoms are present, and applying ice or anti-inflammatory measures to affected joints. Persistent or severe joint symptoms should prompt evaluation by a healthcare provider and consideration of MK-677 discontinuation.

• Musculoskeletal complaints (arthralgia, myalgia) reported in approximately 5-15% of clinical trial subjects
• Carpal tunnel-like symptoms (hand/wrist tingling, numbness) in approximately 3-8% at 25 mg daily
• Caused by IGF-1-mediated connective tissue growth and fluid retention in confined joint spaces
• Elderly subjects more susceptible due to pre-existing degenerative joint changes
• Dose-dependent and typically reversible with dose reduction or discontinuation
• Management: dose reduction to 10-15 mg, cycling protocols, nighttime wrist splints, anti-inflammatory measures

Prolactin and Cortisol Elevation

MK-677 has been shown to produce modest elevations in prolactin and cortisol levels, effects that are mechanistically related to its ghrelin-mimetic activity. Ghrelin receptor activation stimulates not only GH release from the anterior pituitary but also modulates the secretion of other pituitary hormones. In the Nass et al. (2008) two-year study, MK-677 produced a transient increase in serum cortisol levels, with the peak cortisol elevation occurring during the first few weeks of treatment and returning toward baseline with continued use. The cortisol increase was modest — typically 10-20% above baseline in the acute phase — and did not reach supraphysiologic levels associated with Cushing-like symptoms. However, individuals who are already under high physiological or psychological stress may be more sensitive to additional cortisol elevation. Prolactin elevation has been documented in MK-677 studies, though the increase is generally small and dose-dependent. At the standard 25 mg dose, prolactin levels may rise by 10-25% above baseline. In most subjects, prolactin levels remained within the normal reference range despite the increase. Clinically significant hyperprolactinemia (prolactin levels high enough to cause symptoms such as gynecomastia in men, menstrual irregularities in women, or decreased libido) is uncommon with MK-677 alone but may become relevant in individuals stacking MK-677 with other compounds that affect prolactin, such as certain anabolic agents or antipsychotic medications. Monitoring baseline prolactin and cortisol levels before starting MK-677 and rechecking at 8 to 12 weeks is prudent, particularly in male users concerned about gynecomastia risk. If prolactin levels rise above the normal reference range and are accompanied by symptoms, dose reduction or discontinuation is appropriate. The cortisol and prolactin effects of MK-677 are generally self-limiting and do not represent major safety concerns for most users at standard doses.

• Cortisol: transient increase of 10-20% above baseline, typically normalizing after initial weeks
• Prolactin: modest elevation of 10-25% above baseline at 25 mg; usually remains within normal range
• Clinically significant hyperprolactinemia (gynecomastia, menstrual changes) is uncommon with MK-677 alone
• Greater concern when stacking MK-677 with other prolactin-elevating compounds
• Monitor baseline prolactin and cortisol before starting; recheck at 8-12 weeks
• Both effects are dose-dependent and generally self-limiting at standard doses

Long-Term Safety Considerations

The longest controlled clinical trial of MK-677 lasted two years (Nass et al., 2008), providing the best available data on extended use but leaving significant gaps in our understanding of truly long-term safety. Several concerns merit consideration for individuals using MK-677 over months or years. Sustained IGF-1 elevation is the most discussed long-term concern. Epidemiological studies have associated chronically elevated IGF-1 levels with modestly increased risk of certain cancers, including prostate, breast, and colorectal cancer, though a direct causal link has not been established. The IGF-1 elevations produced by MK-677 at 25 mg daily are generally moderate — the Nass study showed approximately 40-60% increases in IGF-1 from baseline — but maintaining IGF-1 levels consistently above the age-adjusted upper limit of normal for extended periods carries at least theoretical oncological risk. Monitoring serum IGF-1 levels every 3 to 6 months and keeping values within the upper-normal range rather than supraphysiologic levels is a commonly recommended approach. The cumulative effect on glucose metabolism is another significant long-term concern. While short-term glucose elevations are typically modest, chronic GH-induced insulin resistance over years could accelerate the progression from normal glucose tolerance to pre-diabetes or type 2 diabetes in susceptible individuals, particularly when combined with a calorie-surplus diet and sedentary lifestyle. The two-year Nass study did show persistent glucose and insulin elevations in the treatment group throughout the study duration, suggesting that metabolic tolerance does not develop with long-term use. Effects on thyroid function have been less well-characterized, though some studies suggest MK-677 may modestly suppress thyroid hormone levels with extended use, potentially through GH-mediated effects on peripheral T4 to T3 conversion. Thyroid function monitoring should be included in long-term blood work panels. Finally, the potential for tachyphylaxis (diminishing GH response over time) with continuous daily dosing has been debated. While GH and IGF-1 elevations were maintained throughout the two-year Nass study, some clinical observations suggest the GH response may attenuate modestly after 6 to 12 months, leading some users to implement cycling strategies to maintain efficacy.

• Longest controlled trial: 2 years (Nass et al., 2008) — truly long-term effects beyond this remain unknown
• Sustained IGF-1 elevation (40-60% above baseline) raises theoretical oncological concerns with chronic use
• Cumulative insulin resistance risk increases with prolonged use — metabolic tolerance does not develop
• Monitor IGF-1 every 3-6 months; aim for upper-normal range, not supraphysiologic levels
• Thyroid function may be modestly affected with extended use — include in routine monitoring
• Cycling strategies (8-12 weeks on, 4 weeks off) may help maintain GH response and mitigate metabolic effects
• Individuals over 50, with metabolic syndrome, or with cancer history should exercise particular caution

References

1. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial (2008) — PubMed
2. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects (1998) — PubMed
3. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (1998) — PubMed
4. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/IGF-I axis in selected GH-deficient adults (1997) — PubMed
5. Neuroendocrine and sleep EEG effects of the growth hormone secretagogue MK-677 in healthy young men (1997) — PubMed
6. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677: effects on body composition and energy expenditure (1998) — PubMed